An interventional study of Bone osteodensitometry in Myeloid Leukemia, Acute, sponsored by University Hospital, Caen. Not yet recruiting at 4 sites in France. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-12-16.
Sponsored by University Hospital, Caen · Not applicable, Interventional, and Other
Evaluation of variation of mineral density and bone microarchitecture after allogeneic HSCTs transplant in hematologic malignancies. Comparison with the general population.
Allo-HSCTs performed for the treatment of hematologic malignancies has been increasing in recent years. There is therefore a growing interest in the quality of life of these patients and in particular for the bone complications of the transplant. Indeed, it was found a high incidence of osteoporosis / osteopenia in this population associated with an increased risk of osteoporotic fracture from 6 to 9 times compared to the general population.
This study will evaluate the variation of mineral density and bone microarchitecture parameters by bone densitometry with measurement of trabecular bone score and fracturing risk before and after allogeneic HSCTs transplant, at predefined times. It's also evaluating pain scale, fracture incidence and bone remodeling markers.
2,971 studies on the registry are indexed under Leukemia, Myeloid, Acute; 745 are open to participants now.
This study's planned enrollment of 120 is above the median of 41 across 2,509 interventional studies indexed under Leukemia, Myeloid, Acute.
Browse Leukemia, Myeloid, Acute studies →University Hospital, Caen is the lead sponsor of 505 studies on the registry; 80 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients with AML
Other: Bone osteodensitometry
Evaluation of bone osteodensitometry
bone mineral density evaluation
bone mineral density evaluation post-transplant
Time frame: change over time between diagnostic, transplant, 6 months and 12 months post-transplant
bone mineral density evaluation
long term bone mineral density evaluation
Time frame: change over time between 24 months and 36 months post-transplant
Bone architectural abnormalities and fracture risk
evaluation of bone architectural abnormalities and fracture risk
Time frame: change over time between diagnostic, transplant, 6 months and 12 months post-transplant
bone remodeling markers
Dosage of bone remodeling markers
Time frame: change over time between diagnostic, transplant, 6 months and 12 months post-transplant
Pain evaluation
Pain evaluation (EVA)
Time frame: change over time between diagnostic, transplant, 6 months, 12 months, 24 months and 36 months post-transplant
Plan to share: No
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Caen